highperformr logo

Cullinan Therapeutics's Overview

Total employees121
HeadquartersCambridge
Founded

Cullinan Oncology is a biopharmaceutical company strategically built to develop a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The company focuses on identifying and developing promising therapeutic candidates, leveraging a hub-and-spoke model to advance multiple programs efficiently. Their mission is to create new standards of care for patients with cancer by bringing innovative treatments from discovery through clinical development and commercialization.

Where is Cullinan Therapeutics's Headquarters?

HQ Function

Serves as the central hub for strategic leadership, research and development oversight, clinical operations management, corporate development, finance, and administrative functions.

Notable Features:

State-of-the-art office facilities within a prominent commercial building in Kendall Square, offering proximity to leading academic institutions, research centers, and biotech peers. The location provides access to a rich innovation ecosystem and talent pool.

Work Culture:

Fosters a dynamic, innovative, and collaborative environment, characteristic of leading biotech companies. The culture emphasizes scientific excellence, urgency in addressing patient needs, and teamwork.

HQ Significance:

Its Cambridge location in Kendall Square places Cullinan Oncology at the epicenter of biopharmaceutical innovation, facilitating collaborations, partnerships, and access to cutting-edge research and talent.

Values Reflected in HQ: The headquarters' location and design reflect Cullinan Oncology's commitment to innovation, scientific rigor, collaboration, and its mission to impact patient lives.

Location:

While headquartered in the United States (Cambridge, MA), Cullinan Oncology has a global outlook for its drug development programs. The company conducts clinical trials in multiple countries and collaborates with international research institutions, investigators, and contract research organizations (CROs) to advance its pipeline. This global approach supports the development and potential future commercialization of its oncology therapies for patients worldwide, though it does not operate a widespread network of international physical offices.

Street Address:

One Main Street, Suite 1350

City:

Cambridge

State/Province:

MA

Country:

USA

Cullinan Therapeutics's Global Presence

N/A - Primarily Cambridge-based

Address: Cullinan Oncology centralizes its core operations at its Cambridge, MA headquarters.

Global reach is achieved through strategic partnerships and clinical trial sites rather than multiple physical offices.

Buying Intent Signals for Cullinan Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Cullinan Therapeutics

As of April 2025, Cullinan Therapeutics' leadership includes:

Nadim Ahmed - Chief Executive Officer
Jeffrey Trigilio - Chief Financial Officer
Jon Wigginton, M.D. - Chief Medical Officer
David C. D. Rubin, M.D. - Chief Business Officer
Corinne Epperly, M.D., M.P.H. - Chief Strategy Officer
Jennifer Michaelson, Ph.D. - Chief Development Officer, Biologics
Anne-Marie D. Martin, Ph.D. - Chief People Officer
Jeffrey Jones, M.D., M.P.H., M.B.A. - Chief Operating Officer

Investors of Cullinan Therapeutics

Cullinan Therapeutics has been backed by several prominent investors over the years, including:

F-Prime Capital
MPM Capital
Boxer Capital (Tavistock Group)
RA Capital Management
Rock Springs Capital
UBS Asset Management (UBS Oncology Impact Fund)
Foresite Capital
Surveyor Capital (a Citadel company)
Matrix Capital Management

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits0

Over the last 12 months, Cullinan Oncology notably expanded its leadership by appointing a new Chief Operating Officer to support its growing pipeline and operational scale. No major executive departures were publicly announced during this period, indicating stability in the senior leadership team.

New Appointments:

Jeffrey Jones, M.D., M.P.H., M.B.A., Dr. Jeffrey Jones joined Cullinan Oncology as Chief Operating Officer, strengthening the executive team.

Technology (Tech Stack) used by Cullinan Therapeutics

Discover the tools Cullinan Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Cullinan Therapeutics Email Formats and Examples

Cullinan Oncology likely utilizes standard corporate email formats for its employees, typically combining parts of an employee's name with the company domain '@cullinanoncology.com'. Common conventions include first initial followed by last name, or first name separated from the last name by a dot.

[first_initial][last]@cullinanoncology.com (e.g., jdoe@cullinanoncology.com) is a common pattern. Another possibility is [first].[last]@cullinanoncology.com.

Format

nahmed@cullinanoncology.com

Example

80%

Success rate

News and media

Business WireMay 9, 2024

Cullinan Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Cullinan Oncology announced its Q1 2024 financial results, highlighting progress in its clinical programs, including CLN-049 in AML and CLN-619 in solid tumors, and detailed upcoming milestones. The company affirmed a strong cash position to fund operations into 2026....more

Business WireFebruary 28, 2024

Cullinan Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Cullinan Oncology reported its financial results for Q4 and full-year 2023, along with a corporate update on its pipeline advancements, including progress with CLN-049, CLN-619, and other key programs....more

Business WireDecember 7, 2023

Cullinan Oncology Presents Updated Data from CLN-049 Phase 1 Dose Escalation Study in Patients with Relapsed/Refractory AML and MDS at ASH 2023

Cullinan Oncology presented updated positive clinical data for its CD123xCD3 T cell engager, CLN-049, at the American Society of Hematology (ASH) 2023 Annual Meeting, demonstrating anti-leukemic activity and a manageable safety profile in patients with r/r AML and MDS....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Cullinan Therapeutics, are just a search away.